Cargando…

Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning

Clinical evidence supports the combination of cabozantinib with an immune checkpoint inhibitor for the treatment of metastatic clear cell renal cell carcinoma (mccRCC) and suggests a synergistic antitumour activity of this combination. Nevertheless, the biological basis of this synergy is not fully...

Descripción completa

Detalles Bibliográficos
Autores principales:	Durán, Ignacio, Castellano, Daniel, Puente, Javier, Martín-Couce, Lidia, Bello, Esther, Anido, Urbano, Mas, José Manuel, Costa, Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794707/ https://www.ncbi.nlm.nih.gov/pubmed/35106125 http://dx.doi.org/10.18632/oncotarget.28183

Ejemplares similares

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib
por: Scirocchi, Fabio, et al.
Publicado: (2021)

Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
por: Vecchio, Sharon J. Del, et al.
Publicado: (2018)

Cabozantinib for the treatment of solid tumors: a systematic review
por: Maroto, Pablo, et al.
Publicado: (2022)

Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma
por: Zhang, Qing, et al.
Publicado: (2017)

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential
por: Bersanelli, Melissa, et al.
Publicado: (2017)

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
por: Iuliani, Michele, et al.
Publicado: (2021)

Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
por: Krens, Stefanie D., et al.
Publicado: (2022)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma
por: Colomba, Emeline, et al.
Publicado: (2022)

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
por: Thouvenin, Jonathan, et al.
Publicado: (2022)

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
por: Wiecek, Witold, et al.
Publicado: (2016)

Cabozantinib combination therapy for the treatment of solid tumors: a systematic review
por: Castellano, Daniel, et al.
Publicado: (2022)

Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma
por: Uche, An, et al.
Publicado: (2019)

Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib
por: Boustany, Johnny, et al.
Publicado: (2020)

Case report: Robust response of metastatic clear cell sarcoma treated with cabozantinib and immunotherapy
por: Sidlik Muskatel, Rakefet, et al.
Publicado: (2022)

Cabozantinib for progressive metastatic medullary thyroid cancer: a review
por: Colombo, Joshua R, et al.
Publicado: (2014)

Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis
por: Lemke, Emily A., et al.
Publicado: (2019)

Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone
por: Yu, Kai-Jie, et al.
Publicado: (2017)

Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma(1)
por: Sharma, Akanksha, et al.
Publicado: (2022)

A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma
por: Kessler, Elizabeth R., et al.
Publicado: (2023)

Erratum to: Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma
por: Sharma, Akanksha, et al.
Publicado: (2023)

Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature
por: Kapur, Sakshi, et al.
Publicado: (2014)

Cabozantinib and IL-27 combinatorial therapy for bone-metastatic prostate cancer
por: Kumar, Shreya, et al.
Publicado: (2023)

The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials
por: Carretero-González, Alberto, et al.
Publicado: (2020)

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
por: Iinuma, Koji, et al.
Publicado: (2022)

Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma
por: Li, Haoran, et al.
Publicado: (2023)

Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma
por: Park, Keon Young, et al.
Publicado: (2021)

Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report
por: Blum, Veronika, et al.
Publicado: (2022)

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
por: Tannir, Nizar M., et al.
Publicado: (2017)

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
por: Santoni, Matteo, et al.
Publicado: (2019)

Complete response of metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus cabozantinib
por: Hayashida, Michikata, et al.
Publicado: (2023)

Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study
por: Pal, Sumanta K., et al.
Publicado: (2021)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
por: Daud, Adil, et al.
Publicado: (2017)

Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study
por: Cerbone, L., et al.
Publicado: (2021)

Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014)

Cabozantinib‐induced renal thrombotic microangiopathy
por: La Manna, Gaetano, et al.
Publicado: (2017)

Cabozantinib and apixaban: an hitherto unreported interaction
por: Santini, Daniele, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_crvpahpssjokdpqr3b8kefb21o